Danaher Corporation $DHR Stock: Sustainable Growth Advisers LP Cuts Position

Sustainable Growth Advisers LP lessened its position in Danaher Corporation (NYSE:DHR) by 28.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,063,782 shares of the conglomerate’s stock after selling 421,516 shares during the quarter. Danaher accounts for approximately 2.6% of Sustainable Growth Advisers LP’s portfolio, making the stock its 15th biggest position. Sustainable Growth Advisers LP’s holdings in Danaher were worth $235,681,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Main Street Group LTD purchased a new position in Danaher during the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC purchased a new stake in Danaher during the second quarter worth about $25,000. Marquette Asset Management LLC increased its stake in Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares during the period. Evolution Wealth Management Inc. increased its stake in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 104 shares during the period. Finally, Field & Main Bank acquired a new stake in shares of Danaher during the second quarter worth about $29,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Guggenheim raised their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Morgan Stanley upped their target price on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank Of Canada increased their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Trading Up 3.0%

DHR opened at $231.52 on Friday. The business has a fifty day moving average price of $213.55 and a 200 day moving average price of $195.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. Sell-side analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.